Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

Published in:

2016

By:

• Mahalingam, D;
• Wilding, G;
• Denmeade, S;
• Sarantopoulas, J;
• Cosgrove, D;
• Cetnar, J;
• Azad, N;
• Bruce, J;
• Kurman, M;
• Allgood, V E;
• Carducci, M

Publication type:

journal article